AnaptysBio Company Profile (NASDAQ:ANAB)

About AnaptysBio (NASDAQ:ANAB)

AnaptysBio logoAnaptysBio, Inc. is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ANAB
  • CUSIP: N/A
  • Web: www.anaptysbio.com
Capitalization:
  • Market Cap: $565.51 million
  • Outstanding Shares: 20,269,000
Average Prices:
  • 50 Day Moving Avg: $24.81
  • 200 Day Moving Avg: $24.62
  • 52 Week Range: $15.17 - $30.71
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.85
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $11.82 million
  • Price / Sales: 44.19
  • Book Value: $5.44 per share
  • Price / Book: 4.74
Profitability:
  • EBIDTA: ($11,660,000.00)
Debt:
  • Debt-to-Equity Ratio: 0.12%
  • Current Ratio: 13.56%
  • Quick Ratio: 13.57%
Misc:
  • Average Volume: 51,378 shs.
  • Short Ratio: 2.76
 
Frequently Asked Questions for AnaptysBio (NASDAQ:ANAB)

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) announced its quarterly earnings data on Thursday, May, 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.57. View AnaptysBio's Earnings History.

Where is AnaptysBio's stock going? Where will AnaptysBio's stock price be in 2017?

5 analysts have issued 12-month price targets for AnaptysBio's shares. Their predictions range from $28.00 to $45.00. On average, they expect AnaptysBio's share price to reach $35.60 in the next year. View Analyst Ratings for AnaptysBio.

Who are some of AnaptysBio's key competitors?

Who are AnaptysBio's key executives?

AnaptysBio's management team includes the folowing people:

  • Hamza Suria, President, Chief Executive Officer, Director
  • Dominic G. Piscitelli, Chief Financial Officer
  • Matthew Moyle Ph.D., Chief Scientific Officer
  • Marco Londei M.D., Chief Medical Officer
  • Hollings C. Renton III, Lead Independent Director
  • Carol G. Gallagher, Independent Director
  • Nicholas Lydon Ph.D., Independent Director
  • John P. Schmid, Independent Director
  • James A. Schoeneck, Independent Director

When did AnaptysBio IPO?

(ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

When did the company's lock-up period expire?

AnaptysBio's lock-up period expired on Tuesday, July 25th. AnaptysBio had issued 5,000,000 shares in its initial public offering on January 26th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Since the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Who owns AnaptysBio stock?

AnaptysBio's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Hamilton Lane Advisors LLC (1.99%). Company insiders that own AnaptysBio stock include Healthcare Vii LP Frazier and Nicholas Lydon. View Institutional Ownership Trends for AnaptysBio.

How do I buy AnaptysBio stock?

Shares of AnaptysBio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AnaptysBio's stock price today?

One share of AnaptysBio stock can currently be purchased for approximately $25.77.


MarketBeat Community Rating for AnaptysBio (NASDAQ ANAB)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  15 (Vote Underperform)
Total Votes:  60
MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AnaptysBio (NASDAQ:ANAB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $35.60 (38.15% upside)

Analysts' Ratings History for AnaptysBio (NASDAQ:ANAB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/10/2017Robert W. BairdInitiated CoverageOutperform -> Outperform$36.00HighView Rating Details
5/2/2017Stifel NicolausBoost Price TargetBuy$30.00 -> $35.00LowView Rating Details
4/18/2017Credit Suisse GroupReiterated RatingOutperform$34.00MediumView Rating Details
3/31/2017JMP SecuritiesReiterated RatingOutperform$45.00HighView Rating Details
3/29/2017WedbushLower Price TargetOutperform$33.00 -> $28.00HighView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for AnaptysBio (NASDAQ:ANAB)
Earnings by Quarter for AnaptysBio (NASDAQ:ANAB)
Earnings History by Quarter for AnaptysBio (NASDAQ ANAB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($0.18)($0.75)$1.63 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AnaptysBio (NASDAQ:ANAB)
2017 EPS Consensus Estimate: ($1.94)
2018 EPS Consensus Estimate: ($2.95)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.24)($0.24)($0.24)
Q2 20171($0.47)($0.47)($0.47)
Q3 20171($0.56)($0.56)($0.56)
Q4 20171($0.67)($0.67)($0.67)
Q1 20181($0.60)($0.60)($0.60)
Q2 20181($0.72)($0.72)($0.72)
Q3 20181($0.83)($0.83)($0.83)
Q4 20181($0.80)($0.80)($0.80)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AnaptysBio (NASDAQ:ANAB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for AnaptysBio (NASDAQ:ANAB)
Institutional Ownership Percentage: 72.59%
Insider Trades by Quarter for AnaptysBio (NASDAQ:ANAB)
Institutional Ownership by Quarter for AnaptysBio (NASDAQ:ANAB)
Insider Trades by Quarter for AnaptysBio (NASDAQ:ANAB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/31/2017Healthcare Vii L.P. FrazierMajor ShareholderBuy400,000$15.00$6,000,000.00View SEC Filing  
1/31/2017Nicholas LydonDirectorBuy16,666$15.00$249,990.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for AnaptysBio (NASDAQ:ANAB)
Latest Headlines for AnaptysBio (NASDAQ:ANAB)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to AnaptysBio, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 6:19 PM
americanbankingnews.com logoAnaptysBio, Inc.'s (NASDAQ:ANAB) Lock-Up Period Set To End on July 25th
www.americanbankingnews.com - July 18 at 10:49 AM
americanbankingnews.com logoAnaptysBio, Inc. (NASDAQ:ANAB) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - July 17 at 4:04 PM
finance.yahoo.com logoETFs with exposure to AnaptysBio, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 5:42 PM
finance.yahoo.com logoAnaptysBio, Inc. breached its 50 day moving average in a Bullish Manner : ANAB-US : July 13, 2017
finance.yahoo.com - July 13 at 4:37 PM
americanbankingnews.com logoRobert W. Baird Initiates Coverage on AnaptysBio, Inc. (NASDAQ:ANAB)
www.americanbankingnews.com - July 10 at 7:14 PM
americanbankingnews.com logoAnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 10 at 7:06 PM
americanbankingnews.com logo$3.13 Million in Sales Expected for AnaptysBio, Inc. (ANAB) This Quarter
www.americanbankingnews.com - July 9 at 8:13 AM
americanbankingnews.com logoZacks: Analysts Anticipate AnaptysBio, Inc. (ANAB) Will Post Earnings of -$0.47 Per Share
www.americanbankingnews.com - July 7 at 10:20 PM
americanbankingnews.com logoZacks: AnaptysBio, Inc. (ANAB) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - July 5 at 9:39 AM
finance.yahoo.com logoAnaptysBio, Inc. – Value Analysis (NASDAQ:ANAB) : June 28, 2017
finance.yahoo.com - June 28 at 4:06 PM
finance.yahoo.com logoAnaptysBio, Inc. breached its 50 day moving average in a Bullish Manner : ANAB-US : June 27, 2017
finance.yahoo.com - June 27 at 3:37 PM
americanbankingnews.com logoBrokerages Expect AnaptysBio, Inc. (ANAB) to Post ($0.47) EPS
www.americanbankingnews.com - June 14 at 6:38 PM
americanbankingnews.com logo Brokerages Expect AnaptysBio, Inc. (ANAB) Will Announce Earnings of -$0.47 Per Share
www.americanbankingnews.com - June 13 at 8:10 PM
finance.yahoo.com logoWhy AnaptysBio (ANAB) Could Be Positioned for a Slump
finance.yahoo.com - June 9 at 3:51 PM
finance.yahoo.com logoAnaptysBio to Participate in Upcoming Investor Conferences
finance.yahoo.com - June 1 at 3:47 PM
finance.yahoo.com logoAnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : May 29, 2017
finance.yahoo.com - May 29 at 3:54 PM
americanbankingnews.com logoZacks: AnaptysBio Inc (ANAB) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - May 29 at 9:06 AM
americanbankingnews.com logo Analysts Expect AnaptysBio Inc (ANAB) Will Post Earnings of -$0.47 Per Share
www.americanbankingnews.com - May 17 at 8:28 AM
americanbankingnews.com logoEquities Analysts Offer Predictions for AnaptysBio Inc's Q2 2017 Earnings (ANAB)
www.americanbankingnews.com - May 17 at 8:08 AM
americanbankingnews.com logoAnaptysBio Inc (ANAB) Releases Earnings Results
www.americanbankingnews.com - May 12 at 11:26 AM
finance.yahoo.com logoAnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update
finance.yahoo.com - May 11 at 8:49 PM
finance.yahoo.com logoAnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : May 11, 2017
finance.yahoo.com - May 11 at 3:47 PM
americanbankingnews.com logoZacks: Brokerages Set $37.67 Target Price for AnaptysBio Inc (ANAB)
www.americanbankingnews.com - May 4 at 11:02 PM
americanbankingnews.com logoStifel Nicolaus Reaffirms "Buy" Rating for AnaptysBio Inc (ANAB)
www.americanbankingnews.com - May 2 at 1:28 PM
americanbankingnews.com logo$1.63 Million in Sales Expected for AnaptysBio Inc (ANAB) This Quarter
www.americanbankingnews.com - April 28 at 5:33 PM
americanbankingnews.com logo-$0.25 Earnings Per Share Expected for AnaptysBio Inc (ANAB) This Quarter
www.americanbankingnews.com - April 26 at 11:44 AM
americanbankingnews.com logoZacks Investment Research Downgrades AnaptysBio Inc (ANAB) to Sell
www.americanbankingnews.com - April 25 at 6:16 PM
finance.yahoo.com logoAnaptysBio, Inc. – Value Analysis (NASDAQ:ANAB) : April 20, 2017
finance.yahoo.com - April 20 at 3:36 PM
finance.yahoo.com logoAnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : April 19, 2017
finance.yahoo.com - April 19 at 3:31 PM
finance.yahoo.com logoAnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : April 19, 2017
finance.yahoo.com - April 19 at 3:31 PM
americanbankingnews.com logoAnaptysBio's (ANAB) "Outperform" Rating Reaffirmed at Credit Suisse Group AG
www.americanbankingnews.com - April 18 at 4:52 PM
americanbankingnews.com logoZacks: AnaptysBio Inc (ANAB) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 18 at 10:34 AM
finance.yahoo.com logoETFs with exposure to AnaptysBio, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 5:50 AM
finance.yahoo.com logoAnaptysBio Announces First-In-Human Dosing of ANB019
finance.yahoo.com - April 7 at 5:50 AM
americanbankingnews.com logo AnaptysBio Inc (ANAB) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - April 6 at 9:34 AM
americanbankingnews.com logoJMP Securities Reaffirms "Outperform" Rating for AnaptysBio Inc (ANAB)
www.americanbankingnews.com - April 6 at 9:31 AM
americanbankingnews.com logoAnaptysBio Inc (ANAB) Given New $28.00 Price Target at Wedbush
www.americanbankingnews.com - April 4 at 8:11 AM
americanbankingnews.com logoAnaptysBio Inc (ANAB) to Post Q1 2018 Earnings of ($0.60) Per Share, Wedbush Forecasts
www.americanbankingnews.com - March 31 at 1:05 PM
americanbankingnews.com logoAnaptysBio Inc (ANAB) Earns Outperform Rating from JMP Securities
www.americanbankingnews.com - March 31 at 12:02 PM
americanbankingnews.com logoAnaptysBio Inc (ANAB) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - March 29 at 4:37 PM
americanbankingnews.com logoAnaptysBio Inc (ANAB) Coverage Initiated at JMP Securities
www.americanbankingnews.com - March 26 at 2:25 PM
us.rd.yahoo.com logoCoverage initiated on AnaptysBio by Credit Suisse, Wedbush, Stifel and JMP Securities
us.rd.yahoo.com - February 22 at 8:35 PM
finance.yahoo.com logoCoverage initiated on AnaptysBio by Wedbush and Stifel
finance.yahoo.com - February 21 at 3:48 PM
finance.yahoo.com logoAnaptysBio to Present Data from ANB020 Program at Two Upcoming Medical Meetings
finance.yahoo.com - February 21 at 7:54 AM
investopedia.com logoRobust Start for Pharmaceutical IPOs In 2017
www.investopedia.com - February 6 at 3:17 PM
wsj.com logo[$$] Braeburn Pharmaceuticals Puts IPO Plans On Hold
www.wsj.com - February 2 at 8:34 PM
wsj.com logo[$$] Shares in Two Biotechs Rise Post-IPO
www.wsj.com - January 31 at 8:45 PM
finance.yahoo.com logoAnaptysBio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - January 31 at 8:45 PM

Social

Chart

AnaptysBio (ANAB) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff